Skip to main content
[Preprint]. 2020 Oct 30:2020.08.13.250217. Originally published 2020 Aug 14. [Version 2] doi: 10.1101/2020.08.13.250217

Fig. 4. Erythromycin inhibits SARS-CoV-2 viral entry.

Fig. 4.

(A) Percent SARS-CoV-2 pseudovirus (SARS2-PV) infection after erythromycin (100 μg/ml) treatment of HEK293T cells over expressing ACE2. Data are expressed as mean ± s.e.m., *P ≤ 0.05, unpaired t test, n=3. (B) Erythromycin (100 μg/ml) increased membrane fluidity in membrane fluidity assay. Data are expressed as mean ± s.e.m., **P ≤ 0.01, unpaired t test, n=3–4. (C) A raft disruption assay based on PLD2 enzymatic activity in HEK293T cells. (D-E) An ELISA assay showing HCQ (50 μM), tetracaine (50 μM), propofol (100 μM), and erythromycin (100 μg/ml) decreased the synthesis of Ab40 in HEK293T cells with (E) and without (D) cholesterol loading (4 μM apolipoprotein E + 10% serum). Data are expressed as mean ± s.e.m., *P ≤ 0.05, **P ≤ 0.01, one-way ANOVA, n=3–7.